Combined dupilumab with immunotherapy is more effective than dupilumab alone in children with moderate-to-severe atopic dermatitis

The addition of subcutaneous immunotherapy (SCIT) to dupilumab in children with moderate-to-severe AD has been shown to maintain substantial efficacy over a longer period than dupilumab alone.